基因变异与乳房外Paget病预后相关:CDKN2A体细胞变异提示不良预后
本研究基于日本全国数据库回顾性分析167例乳房外Paget病(EMPD)患者,其中127例有生存数据。CDKN2A loss为最常见变异;CDKN2A突变组(n=72)预后显著差于野生型组(n=55;HR 1.81,95%CI 1.06-3.07,P=0.029);BRCA2突变组(n=18)亦差于野生型组(n=109;HR 2.97,95%CI 1.46-6.01,P=0.003)。
要点
- CDKN2A变异(主要为loss)与EMPD不良预后相关。
- BRCA2突变EMPD患者预后亦较差。
- ECOG-PS 1时行CGP检测者中位生存<9个月。
核心结论
- 体细胞CDKN2A变异(主要为loss)可能与EMPD不良预后相关。
- BRCA2突变EMPD患者亦可能预后更差。
- 建议在ECOG-PS恶化前进行CGP检测。
研究设计与样本
- 回顾性队列研究,数据来自日本癌症基因组学与先进治疗中心数据库(截至2024年1月)。
- 共记录167例EMPD患者,其中127例纳入生存分析。
主要发现
- CDKN2A loss为数据库中最常见的基因变异。
- BRCA2突变组(n=18)较野生型组(n=109)预后更差:HR 2.97,95%CI 1.46-6.01,P=0.003。
- CDKN2A突变组(n=72)较野生型组(n=55)预后显著更差:HR 1.81,95%CI 1.06-3.07,P=0.029。
- CDKN2A变异多为致病性,以loss为主;BRCA2变异多为意义未明变异。
- CGP入组时ECOG-PS 1者较ECOG-PS 0者预后显著更差(P=0.034;中位生存时间531 vs. 259天)。
关键数值与推荐
- BRCA2突变组 vs 野生型组:HR 2.97,95%CI 1.46-6.01,P=0.003。
- CDKN2A突变组 vs 野生型组:HR 1.81,95%CI 1.06-3.07,P=0.029。
- ECOG-PS 1 vs 0:P=0.034;中位生存时间531 vs. 259天。
临床怎么用
- 对EMPD患者可考虑检测CDKN2A及BRCA2变异以辅助预后评估。
- 建议在ECOG-PS恶化前完成CGP检测以指导治疗规划。
局限性
- 回顾性数据库研究,存在长度偏倚并采用Kaplan-Meier法校正。
- BRCA2变异多为意义未明变异,解读需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have reported the mutational landscape in extramammary Paget disease (EMPD); however, the prognostic implications of genetic alterations remain unexplored. While CDKN2A loss is known to be associated with tumour progression or poor prognosis in some types of cancer, its significance in EMPD has not been investigated. OBJECTIVES: To examine the association between common genetic alterations and prognosis in EMPD. METHODS: A retrospective cohort study was carried out to analyse the data of patients with EMPD registered up to January 2024 in the Center for Cancer Genomics and Advanced Therapeutics database, a nationwide database that records clinical data and comprehensive genomic profiling (CGP) test results in Japan. RESULTS: A total of 167 patients with EMPD were recorded in the database, with CDKN2A loss being the most frequent genetic variant. Survival analysis was conducted on data from 127 patients. Survival from the initiation of chemotherapy was analysed, adjusting for length bias inherent in the database with the Kaplan-Meier estimator, an established method of adjustment. Patients with BRCA2-mutant tumours (n = 18) had a worse prognosis than those with BRCA2 wildtype (WT) tumours [n = 109; hazard ratio (HR) 2.97, 95% confidence interval (CI) 1.46-6.01 (P = 0.003)]. Additionally, patients in the CDKN2A mutant group (n = 72) had a significantly worse prognosis compared with those in the CDKN2A WT group [n = 55; HR 1.81, 95% CI 1.06-3.07 (P = 0.029)]. Most CDKN2A variants were pathogenic, primarily characterized by loss, while most BRCA2 variants were variants of uncertain significance. In the survival analysis of CGP enrolment based on Eastern Cooperative Oncology Group performance status (ECOG-PS), patients with an ECOG-PS of 1 at the time of CGP enrolment had a significantly poorer prognosis compared with those with an ECOG-PS of 0 (P = 0.034; median survival time 531 vs. 259 days). CONCLUSIONS: A somatic CDKN2A variant, mainly exhibiting loss, may be associated with a poor prognosis in EMPD. Patients with EMPD with BRCA2-mutant disease might also have a worse prognosis. In addition, CGP testing before ECOG-PS deteriorates is preferable, considering that the observed median survival of individuals undergoing CGP tests in an ECOG-PS 1 condition was < 9 months. Extramammary Paget disease (‘EMPD’) is a rare skin cancer that usually appears in the genital area. Little is known about how genetic changes affect the prognosis of people with the disease. This study was carried out in Japan using a national database. The database included the information of people who had undergone in-depth tests to examine genetic changes in their cancer. We aimed to explore the relationship between specific genetic changes and the prognosis of patients with EMPD. To do this, we looked at 167 patients in the database, focusing on 127 people for whom survival data was available. Our main goal was to see how genetic changes might affect patient survival. In our cohort, a gene called ‘CDKN2A’ was the most frequently changed, and we found that changes to CDKN2A were linked to poorer prognosis. Similarly, patients who had changes to a gene called ‘BRCA2’ also had a poorer prognosis. We also noted that earlier testing for genetic changes could lead to better treatment planning and outcomes. In conclusion, identifying changes in the ‘CDKN2A’ gene in patients with EMPD may be related to a poor prognosis. These new findings may help doctors create more personalized treatment plans for people with EMPD. Understanding these genetic factors also opens new research opportunities in EMPD.
引用
- Iwasawa O, Ikegami M, Miyagawa T, et al. Association of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic CDKN2A variants in patients with a poor prognosis. Br J Dermatol. 2024. PMID: 39172540. doi:10.1093/bjd/ljae337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。